A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER | NYU Langone Health

Go Back to All Clinical Trials

A PHASE 1B OPEN-LABEL MULTICENTER STUDY TO INVESTIGATE THE SAFETY AND PRELIMINARY EFFICACY OF NKTR 214 IN COMBINATION WITH ANTI-PD-1 (PEMBROLIZUMAB) FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA LOCALLY ADVANCED OR METASTATIC UROTHELIAL BLADDER CANCER OR METASTATIC NON-S ALL CELL LUNG CANCER

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Melanoma, Bladder Cancer, Nsclc, Urothelial Carcinoma
Age: Between 18 years - 99 years
Gender: Male or Female

Other Inclusion Criteria:
1. 1. Histologically confirmed locally advanced or metastatic melanoma, locally advanced or metastatic urothelial carcinoma, or metastatic non-small cell lung cancer (NSCLC)
2. 2. Patients must not have received prior interleukin-2 (IL-2) therapy
3. 3. Significant toxic effect(s) of the most recent prior chemotherapy must be resolved (except alopecia and sensory neuropathy).

You may not be eligible for this study if the following are true:

1. 1. Use of an investigational agent or an investigational device within 28 days before administration of first dose of study drug(s)
2. 2. Patients who have an active, known or suspected autoimmune disease
3. 3. History of allergy or hypersensitivity to study drug components.